Patient expectations of benefit from systemic treatments for metastatic prostate cancer
Abstract Background Metastatic prostate cancer is incurable, but systemic therapies can improve quality of life and prolong survival. Accurate perceptions of treatment risks and benefits are vital as patients with metastatic disease make treatment decisions. We assessed treatment‐related expectation...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2783 |
| _version_ | 1798023210060480512 |
|---|---|
| author | Laura B. Oswald Rachel Kasimer Katherine Rappazzo Angela J. Fought David F. Penson Alicia K. Morgans |
| author_facet | Laura B. Oswald Rachel Kasimer Katherine Rappazzo Angela J. Fought David F. Penson Alicia K. Morgans |
| author_sort | Laura B. Oswald |
| collection | DOAJ |
| description | Abstract Background Metastatic prostate cancer is incurable, but systemic therapies can improve quality of life and prolong survival. Accurate perceptions of treatment risks and benefits are vital as patients with metastatic disease make treatment decisions. We assessed treatment‐related expectations for benefit among patients with metastatic prostate cancer and explored associated sociodemographic characteristics. Methods Men with metastatic prostate cancer (N = 100) completed surveys assessing their treatment‐related expectations for cancer cure, symptom relief, and prolonged life expectancy. Frequencies were used to describe the proportions of reported expectations. Fisher's exact tests were used to assess the associations of sociodemographic characteristics with treatment expectations. Results One third (33%) of participants believed treatment was at least a little likely to cure their metastatic cancer. Most participants believed treatment could provide symptom relief (76%) and extend life expectancy (95%). Among participants reporting that cancer cure was at least a little likely vs not at all, more men identified as non‐white (24% vs 5%; P = .01), self‐reported good health (90% vs 58%; P < .01), and had greater optimism (78% vs 47%; P < .01). Among participants reporting that symptom relief was at least a little likely vs not at all, more men were less than 70 years old (62% vs 0%; P = .01). Conclusion A large proportion of patients with metastatic prostate cancer reported beliefs inconsistent with understanding that treatment was not curative. Race, better self‐reported health, and greater optimism were related to unrealistic expectations. Efforts to ensure alignment of patient and clinician expectations may facilitate more effective shared decision‐making for treating metastatic disease. |
| first_indexed | 2024-04-11T17:42:37Z |
| format | Article |
| id | doaj.art-a94820519a1c474cb66b1f90955e941a |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-11T17:42:37Z |
| publishDate | 2020-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-a94820519a1c474cb66b1f90955e941a2022-12-22T04:11:27ZengWileyCancer Medicine2045-76342020-02-019398098710.1002/cam4.2783Patient expectations of benefit from systemic treatments for metastatic prostate cancerLaura B. Oswald0Rachel Kasimer1Katherine Rappazzo2Angela J. Fought3David F. Penson4Alicia K. Morgans5Northwestern University Feinberg School of Medicine Chicago IL USANorthwestern University Feinberg School of Medicine Chicago IL USAJohns Hopkins University Baltimore MD USAUniversity of Colorado Denver CO USAVanderbilt University Medical Center Nashville TN USANorthwestern University Feinberg School of Medicine Chicago IL USAAbstract Background Metastatic prostate cancer is incurable, but systemic therapies can improve quality of life and prolong survival. Accurate perceptions of treatment risks and benefits are vital as patients with metastatic disease make treatment decisions. We assessed treatment‐related expectations for benefit among patients with metastatic prostate cancer and explored associated sociodemographic characteristics. Methods Men with metastatic prostate cancer (N = 100) completed surveys assessing their treatment‐related expectations for cancer cure, symptom relief, and prolonged life expectancy. Frequencies were used to describe the proportions of reported expectations. Fisher's exact tests were used to assess the associations of sociodemographic characteristics with treatment expectations. Results One third (33%) of participants believed treatment was at least a little likely to cure their metastatic cancer. Most participants believed treatment could provide symptom relief (76%) and extend life expectancy (95%). Among participants reporting that cancer cure was at least a little likely vs not at all, more men identified as non‐white (24% vs 5%; P = .01), self‐reported good health (90% vs 58%; P < .01), and had greater optimism (78% vs 47%; P < .01). Among participants reporting that symptom relief was at least a little likely vs not at all, more men were less than 70 years old (62% vs 0%; P = .01). Conclusion A large proportion of patients with metastatic prostate cancer reported beliefs inconsistent with understanding that treatment was not curative. Race, better self‐reported health, and greater optimism were related to unrealistic expectations. Efforts to ensure alignment of patient and clinician expectations may facilitate more effective shared decision‐making for treating metastatic disease.https://doi.org/10.1002/cam4.2783metastatic diseaseprognostic understandingprostate cancersystemic treatmentstreatment expectations |
| spellingShingle | Laura B. Oswald Rachel Kasimer Katherine Rappazzo Angela J. Fought David F. Penson Alicia K. Morgans Patient expectations of benefit from systemic treatments for metastatic prostate cancer Cancer Medicine metastatic disease prognostic understanding prostate cancer systemic treatments treatment expectations |
| title | Patient expectations of benefit from systemic treatments for metastatic prostate cancer |
| title_full | Patient expectations of benefit from systemic treatments for metastatic prostate cancer |
| title_fullStr | Patient expectations of benefit from systemic treatments for metastatic prostate cancer |
| title_full_unstemmed | Patient expectations of benefit from systemic treatments for metastatic prostate cancer |
| title_short | Patient expectations of benefit from systemic treatments for metastatic prostate cancer |
| title_sort | patient expectations of benefit from systemic treatments for metastatic prostate cancer |
| topic | metastatic disease prognostic understanding prostate cancer systemic treatments treatment expectations |
| url | https://doi.org/10.1002/cam4.2783 |
| work_keys_str_mv | AT lauraboswald patientexpectationsofbenefitfromsystemictreatmentsformetastaticprostatecancer AT rachelkasimer patientexpectationsofbenefitfromsystemictreatmentsformetastaticprostatecancer AT katherinerappazzo patientexpectationsofbenefitfromsystemictreatmentsformetastaticprostatecancer AT angelajfought patientexpectationsofbenefitfromsystemictreatmentsformetastaticprostatecancer AT davidfpenson patientexpectationsofbenefitfromsystemictreatmentsformetastaticprostatecancer AT aliciakmorgans patientexpectationsofbenefitfromsystemictreatmentsformetastaticprostatecancer |